P153/189 Economic impact of improved functional outcomes associated with the embotrap device vs. trevo retriever and solitaire revascularization device for treatment of acute ischemic stroke: an economic analysis of mastro i from a german hospital perspective

ConclusionThe use of EmboTrap in Germany may lead to reduction in short-term hospital costs, compared to Solitaire or Trevo due to improved patient functional outcomes (90-day mRS 0–2). These findings may inform evidence-based decision making when selecting a cost-efficient SR for MT.Disclosure of InterestOsama Zaidat reports consulting fees for Stryker, Medtronic, Cerenovus, and Penumbra; research grants from Stryker, Medtronic, Cerenovus, Penumbra, and Genentech; in addition, Dr Zaidat had a patent for ischemic stroke issued.Tommy Andersson is a consultant for Anaconda, Cerenovus, Neuravi and Rapid Medical, and holds equity in Ceroflo.Mina Kabiri is an employee of Johnson & Johnson.Shanti Scheffler is an employee of Johnson & Johnson.Emilie Kottenmeier is an employee of Johnson & Johnson.
Source: Journal of NeuroInterventional Surgery - Category: Neurosurgery Authors: Tags: 2.3 ISCHEMIC - Treatment Source Type: research